First Quarter 2021

Report Ÿ

Zealand Pharma

12 May 2021

Forward looking statement

This presentation contains "forward-looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products.

The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward- looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition.

If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.

All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

1Q 2021 presentation 12 May 2021

2

Secure strong financial situation
Invest in innovative peptide research platform and robust pipeline

With the Zegalogue approval we have taken another important step in pursuing our ambition as a fully integrated biotech

5x25

Have 5 commercialized products by 2025

Optimize commercial operations

DKK thousand

Fully operational US

2,000,000

infrastructure

1,500,000

High prescriber coverage

1,000,000

Established relationships

500,000

with KOLs and HCPs

0

2017

2018

2019

2020

Q1 2021

Cash & cash equivalents

Restricted cash

Securities

1Q 2021 presentation 12 May 2021

3

Four strategic objectives to ensure a successful launch of ZEGALOGUE

Presence

Precision

Establish a clear and distinct product positioning with HCPs, patients, and caregivers

Focused execution during the "back to school" season prioritizing high-value customer segments

Access

Support

Establish favorable market access early among top National and Regional Payers, PBMs, and health systems

Address patient and caregiver access and education needs through a "fit for purpose" patient support capability

1Q 2021 presentation 12 May 2021

4

ZEGALOGUE will launch at the right time in a growing market that is driven by innovation

Launch timed to capture

'Back to school' seasonality

+60% Rx Volume Lift

TRx Volume

Weekly Glucagon Market

Jun Jul Aug Sep Oct

Source: Symphony Health TRx Quantity

Rescue market growing with

Innovation driven market with

new entrants

new entrants capturing share

TRx Units Dispensed (M)

1.2

+10%

+6%

0.9

~300m

USD

63%

78%

0.6

100%

1.0

0.90.9

0.3

37%

22%

0.0

2019

2020

2018

2019

2020

2018

Legacy products

New Entrants

1Q 2021 presentation 12 May 2021

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Zealand Pharma A/S published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 16:47:03 UTC.